Tolerogenicity of Resting and Activated B Cells
Overview
General Medicine
Authors
Affiliations
Antigen presentation by resting splenic B cells has been shown previously to induce T helper 1 cell (Th1) anergy. In contrast to expectations, it was found here that B cells treated with F(ab')2 goat anti-mouse immunoglobulin (IgM) for 24 or 48 h also presented antigen (Ag) to Th1 cells in a manner that induced dramatic Ag-specific proliferative inactivation. The tolerogenicity of the anti-Ig-treated B cells was consistent with the observation that these B cells were only slightly more efficient than resting B cells in stimulating human gamma globulin (HGG)-induced proliferation of HGG-specific Th1 cells in primary cultures. The activated B cells were, however, more efficient than resting B cells in stimulating a primary mixed leukocyte reaction, and exhibited increased expression of major histocompatibility complex class II molecules, RL388 Ag and transferrin receptor. In addition, unlike resting B cells, which expressed little detectable B7, anti-Ig-treated B cells expressed high levels of B7. The functional capacity of the B7 expressed on the activated B cells was demonstrated by the fact that the Ag-presenting capacity of these B cells was inhibited by the addition to culture of CTLA4Ig, a soluble receptor for B7. It is unlikely that the tolerogenicity of the activated B cells was due to an inability of the Th1 cells to respond to B7 signals; the Th1 clones used in the experiments, unlike the Th2 clones tested, expressed CD28, the ligand for B7. In addition, anti-CD28 monoclonal antibody inhibited the induction of Th1 cell anergy when added to cultures of Th1 cells and Ag-pulsed fixed antigen-presenting cells. Taken together, the results indicate that B cells, even when activated, do not satisfy the costimulatory requirements of the Th1 cells used here, and therefore can present Ag in a tolerogenic fashion to Th1 cells. The costimulator deficiency of activated B cells may reflect an inadequacy in the level of B7 expressed or a lack of some other molecule.
Vector Strategies to Actualize B Cell-Based Gene Therapies.
Jeske A, Boucher P, Curiel D, Voss J J Immunol. 2021; 207(3):755-764.
PMID: 34321286 PMC: 8744967. DOI: 10.4049/jimmunol.2100340.
Inhibitors - cellular aspects and novel approaches for tolerance.
Scott D Haemophilia. 2014; 20 Suppl 4:80-6.
PMID: 24762281 PMC: 4205104. DOI: 10.1111/hae.12407.
Matheu M, Su Y, Greenberg M, Blanc C, Parker I, Scott D Proc Natl Acad Sci U S A. 2012; 109(20):E1258-66.
PMID: 22511718 PMC: 3356607. DOI: 10.1073/pnas.1205150109.
Mathieu M, Cotta-Grand N, Daudelin J, Boulet S, Lapointe R, Labrecque N PLoS One. 2012; 7(1):e30139.
PMID: 22291907 PMC: 3264565. DOI: 10.1371/journal.pone.0030139.
Multiple vaccinations: friend or foe.
Church S, Jensen S, Twitty C, Bahjat K, Hu H, Urba W Cancer J. 2011; 17(5):379-96.
PMID: 21952289 PMC: 3614402. DOI: 10.1097/PPO.0b013e3182346320.